The International Consortium of Lithium Genetics (ConLiGen): Achievements and Collaborations

Heilbronner U., PhD
Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich

Summary. Lithium is an indispensable tool of modern psychiatry. Although it is well-known that response to lithium is a familial trait, available research on pharmacogenetics regarding lithium treatment has, in the past, produced few reproducible results. The Consortium of Lithium Genetics (ConLiGen) was initiated by Thomas G. Schulze and Francis J. McMahon in 2008 to overcome these limitations. To date, researchers from 39 countries have joined the consortium, making it a truly international effort. A hallmark of the consortium is the use of an 11-point lithium response rating scale defined by Martin Alda and colleagues. The pooling of genotype data from over 2,500 patients phenotyped with this standardized response scale, have led to initial successes, which form the basis for further research.

Keywords: bipolar disorder; medication; collaboration, GW AS; response; ALDA scale; genomics.

Lithium has been successfully used to treat bipolar disorder for more than 50 years. Apart from its proven antimanic and prophylactic effects, there is also evidence that suggests an antisuicidal effect in affective disorders, making it an indispensable tool of modern psychiatry (Papiol, Schulze, & Alda, 2018). However, response to lithium is variable, with only about 30% of bipolar patients responding to treatment (Garnham et al., 2007). Although it is well-known that response to lithium is a familial trait (e.g. Grof et al., 2002), available research on pharmacogenetics regarding lithium treatment has, in the past, produced few reproducible results (see e.g. Pisanu, Heilbronner, & Squassina, 2018). To overcome this limitation, ConLiGen was initiated by Thomas G. Schulze and Francis J. McMahon at the National Institutes of Health, USA, based upon a meeting which took place at NIMH on May 6, 2008 (Schulze et al., 2010). ConLiGen aims to identify genetic determinants of response to lithium treatment in bipolar disorder, as well as genetic determinants of adverse events emerging during lithium treatment. To date, researchers from 39 countries have joined the consortium, making it a truly international effort. As response phenotype for lithium treatment, ConLiGen has been using an 11-point rating scale defined by Martin Alda and colleagues (Grof et al., 2002). While an important goal of ConLiGen is to further study this response phenotype (Manchia et al., 2013; Scott et al., 2019), another focus is to facilitate well-powered genome-wide association studies (GWAS). In an initial effort (Hou, Heilbronner, et al., 2016), data from over 20 clinical centers have been pooled to perform an initial GWAS of more than 2,500 individuals in which lithium response had been measured. This study identified four SNPs associated with response to lithium. Furthermore, ConLiGen data has been used in several additional publications (Amare et al., 2018; Hou, Bergen, et al., 2016; Kalman et al., 2019; Reinbold et al., 2018). In the future ConLiGen’s focus will be on expanding internationally, collecting more lithium response data and biomaterial to replicate previous findings. Also, another aim is more comprehensive phenotyping, to develop predictive models of lithium response.
References


Сведения об авторах

Urs Heilbroner — PhD, Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich